XML 27 R14.htm IDEA: XBRL DOCUMENT
v3.20.4

Stock-based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stock-based Compensation | NOTE 8—Stock-based Compensation As of December 31, 2020, the Company had the 2012 Equity Incentive Plan (the “2012 Option Plan”) and 2019 Equity Incentive Plan (the “2019 Option Plan”) and the 2019 Employee Stock Purchase Plan in place. As of December 31, 2020, the number of shares available to be issued under the 2019 Option Plan were 2,921,714. In May 2020, the Board of Directors approved an increase in the number of shares of common stock reserved for future issuance under the 2019 Option Plan to 3,000,000 shares, which was approved by the Company’s stockholders on September 29, 2020. As of December 31, 2020, the number of shares available to be issued under the 2019 Employee Stock Purchase Plan was 280,438. The 2019 Option Plans provides for the grant of incentive and non-statutory stock options (“Options”), stock appreciation rights (“SAR”), restricted stock awards (“RSA”), and restricted stock unit awards (“RSU”) to employees, nonemployee directors, and consultants of the Company. Option awards granted under the 2019 Option Plan generally become exercisable ratably over a two-year or four-year period following the date of grant and expire ten years from the date of grant. At the discretion of the Board of Directors, certain awards may be exercisable immediately at the date of grant but are subject to a repurchase right, under which the Company may buy back any unvested shares at their original exercise price in the event of an employee’s termination prior to full vesting. All other awards are exercisable only to the extent vested. At, December 31, 2020 and 2019, there were no shares that had been early exercised that were subject to the Company’s repurchase right at that date. The exercise price or strike price for Options and SARs granted under the 2019 Option Plan must generally be at least equal to 100% of the fair value of the Company’s common stock at the date of grant, as determined by the Board of Directors. The exercise price of incentive stock options granted under the 2019 Option Plan to ten percent or greater stockholders must be at least equal to 110% of the fair value of the Company’s common stock at the date of grant, as determined by the Board of Directors, and are not exercisable after five years from the date of grant. The Board of Directors adopted, and its stockholders approved, the 2019 Employee Stock Purchase Plan and the 2019 Option Plan in March 2019 and April 2019, respectively, each of which became effective in connection with the IPO. There are 541,379 shares of common stock reserved for issuance under the 2019 Employee Stock Purchase Plan as of December 31, 2020. Additionally, the number of shares of common stock reserved for issuance under the 2019 Employee Stock Purchase Plan automatically increases on January 1 of each calendar year for 10 years, starting January 1, 2020, and ending on, and including, January 1, 2029, in an amount equal to the lesser of 1% of the total number of shares of capital stock outstanding on December 31st of the prior calendar year, and (ii) 500,000 shares, unless the Board of Directors or the compensation committee of the Board of Directors determines prior to such date that there will be a lesser increase, or no increase. The increase under the 2019 Employee Stock Purchase Plan for 2020 was 204,372 shares. As of December 31, 2020, 5,906,900 shares of common stock are reserved for future issuance under the 2019 Option Plan, plus the number of shares subject to outstanding stock options or other stock awards that were granted under the 2012 Option Plan that are forfeited, terminated, expire or are otherwise not issued. Additionally, the number of shares of common stock reserved for issuance under the 2019 Option Plan automatically increases on January 1 of each calendar year for 10 years, starting January 1, 2020 and ending on and including January 1, 2029, in an amount equal to 5% of the total number of shares of capital stock outstanding on December 31 of the prior calendar year, unless the Board of Directors or compensation committee determines prior to the date of increase that there will be a lesser increase, or no increase. The increase under the 2019 Option Plan for 2020 was 1,021,861 shares. As of December 31,2020, 192,335 shares of common stock were issued under the 2019 Employee Stock Purchase Plan. On June 9, 2020, the Company granted an aggregate of 2,015,500 restricted stock units to the Company’s board of directors, executives and employees. On September 29, 2020, the Company granted an aggregate of 676,500 restricted stock units to the Company’s executives and employees. On December 14, 2020, the Company granted an aggregate of 114,000 restricted stock units to an ex-member of the board of directors who will be serving in a consulting capacity. On April 10, 2019, the Company granted an aggregate of 128,000 restricted stock units to the Company’s executives, of which 38,000 were forfeited and 90,000 are outstanding at December 31, 2019. On May 13, 2019, the Company granted a fully vested restricted stock award of 383,197 shares and issued 210,758 net shares of common stock after withholding 172,439 shares of common stock totaling $1,897, recorded as a reduction to additional paid-in capital, to satisfy tax obligations associated with the grant, to the Company’s Chief Executive Officer as a bonus pursuant to his employment agreement. As a result, the Company recorded $4,215 as compensation expense to operating expenses under the Statement of Operations during the year ended December 31, 2019. In connection with the IPO, the Company accelerated vesting of 201,666 options dated September 10, 2018, pursuant to the employment agreement of the Company’s prior Chief Financial Officer. As a result, the Company recorded $287 as compensation expense to operating expenses under the Statement of Operations during year ended December 31, 2019. Stock-based compensation expense is as follows:
|  | For the Year Ended |
|  | December 31 |
|  | 2020 |  |  | 2019 |
Research and development |  | $ | 252 |  |  | $ | 394 |
Sales and marketing |  |  | 230 |  |  |  | 664 |
General and administrative |  |  | 548 |  |  |  | 5,208 |
Cost of revenues |  |  | 57 |  |  |  | 42 |
|  | $ | 1,087 |  |  | $ | 6,308 |
Stock Options: Stock option activity for the years ended December 31, 2020 and 2019 is as follows:
|  |  |  |  |  | Weighted average exercise price |  |  | Weighted average remaining contractual life |  |  | Aggregate Intrinsic |
|  | Options |  |  | per share |  |  | (in years) |  |  | Value |
Outstanding at January 1, 2019 |  |  | 1,320,197 |  |  | $ | 0.77 |  |  |  | 7.99 |  |  | $ | 8,465 |
Options granted |  |  | 1,635,853 |  |  | $ | 5.94 |  |  |  |  |  |  |  |  |
Options exercised |  |  | (95,739 | ) |  | $ | 0.85 |  |  |  |  |  |  |  |  |
Options forfeited |  |  | (186,266 | ) |  | $ | 7.02 |  |  |  |  |  |  |  |  |
Options cancelled |  |  | (28,331 | ) |  |  | 2.72 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2019 |  |  | 2,645,714 |  |  | $ | 3.50 |  |  |  | 8.51 |  |  | $ | 4,184 |
Options granted |  |  | 26,000 |  |  | $ | 0.86 |  |  |  |  |  |  |  |  |
Options exercised |  |  | (541,268 | ) |  | $ | 0.71 |  |  |  |  |  |  |  |  |
Options forfeited |  |  | (510,755 | ) |  | $ | 4.73 |  |  |  |  |  |  |  |  |
Options cancelled |  |  | (175,751 | ) |  | $ | 7.04 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 1,443,940 |  |  | $ | 3.64 |  |  |  | 7.82 |  |  | $ | 24 |
Vested and expected to vest at December 31, 2020 |  |  | 1,443,940 |  |  | $ | 3.64 |  |  |  | 7.82 |  |  | $ | 24 |
Exercisable at December 31, 2020 |  |  | 669,852 |  |  | $ | 4.19 |  |  |  | 6.62 |  |  | $ | 24 |
As of December 31, 2020, there was approximately $3,298 of unamortized stock-based compensation cost related to unvested stock options, which is expected to be recognized over a weighted average period of three years. The total pre-tax intrinsic value of options exercised during the years ended December 31, 2020 and 2019 was $50 and $266, respectively. The intrinsic value is the difference between the estimated fair value of the Company’s common stock at the date of exercise and the exercise price for in-the-money options. The weighted average grant date calculated value of options granted during the years ended December 31, 2020 and 2019 was $0.41 and $2.84, respectively. The fair value of employee stock options is determined using the Black-Scholes option-pricing model using various inputs, including the Company’s estimates of the fair value of common stock on the date of grant, expected term, expected volatility, risk-free interest rate, and expectations regarding future dividends. Share-based compensation also reflects the Company’s estimate regarding the portion of awards that may be forfeited. The following describes the key inputs used by the Company: Fair Value of Common Stock— The Company measures equity classified stock-based awards granted to employees and directors based on the estimated fair value on the date of grant and the expense is recognized on a straight-line basis, over the vesting period. We account for forfeitures as they occur. Expected Term—The expected term represents the period that the Company’s stock options are expected to be outstanding. The majority of stock option grants are considered to be “plain vanilla” and thus the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options. Expected Volatility—The expected volatility was derived from the historical stock volatilities of several unrelated public companies within the Company’s industry that the Company considers to be comparable to the business over a period equivalent to the expected term of the stock option grants. The Company completed its IPO in May 2019, and therefore does not have sufficient history. Risk-Free Interest Rate—The risk-free interest rate is based on the interest yield in effect at the date of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the option’s expected term. Dividend Rate—The expected dividend rate was assumed to be zero, as the Company has not previously paid dividends on common stock and has no current plans to do so. Forfeiture Rate—Forfeitures are recognized when they occur. Historically, the Company estimated the forfeiture rate based on an analysis of actual forfeiture experience, analysis of employee turnover behavior, and other factors. The calculated fair value of option grants made during the years ended December 31, 2020 and 2019, were estimated using the following Black-Scholes option pricing model assumptions:
|  | 2020 |  |  | 2019 |
Expected dividend yield |  |  | 0 | % |  |  | 0 | %
Risk-free interest rate |  | 0.26%-0.46% |  |  | 1.59%-2.33% |
Expected volatility |  |  | 50 | % |  |  | 50 | %
Expected life (in years) |  |  | 6.25 |  |  |  | 6.25 |
Restricted Stock Awards: As of December 31, 2020, and 2019, the unvested restricted stock units totaled 2,691,375 and 249,500 shares, respectively. The following table summarized the outstanding RSU’s as of December 31, 2020:
|  | RSU's |
Outstanding at January 1, 2020 |  |  | 249,500 |
Granted |  |  | 2,806,000 |
Released |  |  | (119,875 | )
Forfeited |  |  | (244,250 | )
Outstanding at December 31, 2020 |  |  | 2,691,375 |
Exercisable at December 31, 2020 |  |  | — |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration